KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Free Cash Flow for 9 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 127.8% year-over-year to $1.0 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 53.27%, and an annual FY2025 reading of $1.1 billion, up 53.27% over the prior year.
  • Free Cash Flow was $1.0 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $233.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.1 billion in Q4 2023 and bottomed at -$555.0 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $200.8 million, with a median of $168.0 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 413.56% in 2021, then soared 5225.0% in 2023.
  • Year by year, Free Cash Flow stood at $303.0 million in 2021, then skyrocketed by 174.26% to $831.0 million in 2022, then increased by 28.16% to $1.1 billion in 2023, then plummeted by 58.12% to $446.0 million in 2024, then surged by 127.8% to $1.0 billion in 2025.
  • Business Quant data shows Free Cash Flow for TEVA at $1.0 billion in Q4 2025, $233.0 million in Q3 2025, and $131.0 million in Q2 2025.